afatinib + rifampicin

**afatinib + rifampicin** is a combination of two small molecule drugs: afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases used primarily as antineoplastic therapy for non-small cell lung cancer (NSCLC), and rifampicin, a potent inducer of P-glycoprotein (P-gp) and a first-line antibiotic for tuberculosis and other bacterial infections. The coadministration is not a recognized combination therapy but is clinically relevant due to known drug-drug interactions in patients who require both drugs. When the two drugs are coadministered, rifampicin significantly reduces plasma exposure of afatinib by inducing P-glycoprotein, which limits afatinib absorption. Thus, concurrent use may result in diminished antineoplastic efficacy of afatinib.

Other names

afatinibrifampin